Compton Jocelyn T, Lee Francis Y
Center for Orthopaedic Research at Columbia University Medical Center, 650 West 168th Street, Box #480 (J.T.C.), Black Building 1412 (F.Y.L.), New York, NY 10032. E-mail address for J.T. Compton:
J Bone Joint Surg Am. 2014 Oct 1;96(19):1659-68. doi: 10.2106/JBJS.M.01096.
➤ Osteocytes, derived from osteoblasts, reside within bone and communicate extensively with other bone cell populations to regulate bone metabolism. The mature osteocyte expresses the protein sclerostin, a negative regulator of bone mass.➤ In normal physiologic states, the protein sclerostin acts on osteoblasts at the surface of bone and is differentially expressed in response to mechanical loading, inflammatory molecules such as prostaglandin E2, and hormones such as parathyroid hormone and estrogen.➤ Pathologically, sclerostin dysregulation has been observed in osteoporosis-related fractures, failure of implant osseous integration, metastatic bone disease, and select genetic diseases of bone mass.➤ An antibody that targets sclerostin, decreasing endogenous levels of sclerostin while increasing bone mineral density, is currently in phase-III clinical trials.➤ The osteocyte has emerged as a versatile, indispensable bone cell. Its location within bone, extensive dendritic network, and close communication with systemic circulation and other bone cells produce many opportunities to treat a variety of orthopaedic conditions.
➤ 骨细胞由成骨细胞分化而来,位于骨组织内,并与其他骨细胞群体广泛交流以调节骨代谢。成熟的骨细胞表达骨硬化蛋白,这是一种骨量的负调节因子。
➤ 在正常生理状态下,骨硬化蛋白作用于骨表面的成骨细胞,并根据机械负荷、前列腺素E2等炎症分子以及甲状旁腺激素和雌激素等激素的刺激而发生差异表达。
➤ 在病理情况下,骨硬化蛋白失调已在骨质疏松相关骨折、种植体骨整合失败、转移性骨病以及某些骨量相关的遗传性疾病中被观察到。
➤ 一种靶向骨硬化蛋白的抗体,可降低内源性骨硬化蛋白水平并增加骨矿物质密度,目前正处于III期临床试验阶段。
➤ 骨细胞已成为一种多功能且不可或缺的骨细胞。它在骨组织中的位置、广泛的树突状网络以及与全身循环和其他骨细胞的紧密交流为治疗多种骨科疾病提供了诸多机会。